Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin

BACKGROUND: A phase I trial was performed to determine the maximum tolerated dose (MTD), safety, pharmacokinetics and immunogenicity of the anti-EpCAM immunotoxin (IT) MOC31PE in cancer patients. An important part of the study was to investigate whether the addition of Sandimmune (cyclosporin, CsA)...

Descripción completa

Detalles Bibliográficos
Autores principales: Andersson, Y, Engebraaten, O, Juell, S, Aamdal, S, Brunsvig, P, Fodstad, Ø, Dueland, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705890/
https://www.ncbi.nlm.nih.gov/pubmed/26554649
http://dx.doi.org/10.1038/bjc.2015.380

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4705890/
https://www.ncbi.nlm.nih.gov/pubmed/26554649
http://dx.doi.org/10.1038/bjc.2015.380

Ejemplares similares